From: Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
Toxicity
Grade 1%
Grade 2
%
Grade 3
Nausea/Vomiting
20
15
5
Mucositis
10
Diarrhea
2.5
Fatigue
Fluid retention*
-
Alopecia
50
35
Neurotoxicity
25
Hypersensitivity reaction